Increased risk in patients w/ known sensitivity to volatile halogenated anaesth agents. Dose-dependent BP decrease; malignant hyperthermia; seizures. Peri-op hyperkalaemia in patients w/ latent & overt neuromuscular disease particularly Duchenne muscular dystrophy. Desiccated CO2
absorbent replacement. Transient elevation in glucose & WBC count. Monitor urine flow during therapy. May affect ability to drive & operate machinery. Concomitant use w/ succinylcholine. Severe hepatic dysfunction; underlying hepatic conditions or use w/ drugs causing hepatic dysfunction. Renal insufficiency (creatinine >1.5 mg/dL). Pregnancy & lactation.